文献速递冠心病心律失常肺血管病与心包/心肌炎

N-乙酰半胱氨酸对动脉血栓的强效溶栓作用

Potent Thrombolytic Effect of N-Acetylcysteine on Arterial Thrombi.
PubMed 文献 · Circulation · 2017-05-09

本研究在小鼠血栓性卒中及颈动脉血栓模型中,发现静脉给予N-乙酰半胱氨酸(NAC)可促进对重组组织型纤溶酶原激活剂、直接凝血酶抑制剂及抗血小板治疗抵抗的动脉血栓溶解,其分子靶点主要为交联血小板的血管性血友病因子(VWF)。NAC与GpIIb/IIIa抑制剂联用进一步改善溶栓疗效及神经结局,且未加重出血性卒中结局。

要点

  • NAC可溶解对rt-PA、直接凝血酶抑制剂及抗血小板治疗抵抗的动脉血栓。
  • NAC溶栓作用的主要分子靶点是交联血小板的VWF。
  • NAC联用GpIIb/IIIa抑制剂加速血栓溶解并防止再血栓形成。

核心结论

  • NAC是对现有抗血栓药物有效的安全替代,可在动脉闭塞后恢复血管通畅。

研究设计与样本

  • 采用动脉内凝血酶注射或氯化铁诱导的血栓性卒中实验模型,结合激光多普勒血流测定与MRI测量脑血流。
  • 进行氯化铁诱导的颈动脉血栓实验以研究NAC对大血管的作用。
  • 体外实验包括血小板聚集测定、富血小板血栓溶解试验、血栓弹力图(ROTEM)及微流控装置高剪切VWF弦形成实验。
  • 在小鼠颅内出血模型(原位注射VII型胶原酶)中研究NAC的潜在促出血效应。

主要发现

  • 静脉给予NAC促进对重组组织型纤溶酶原激活剂、直接凝血酶抑制剂及抗血小板治疗抵抗的动脉血栓溶解。
  • 体外和体内实验提供证据表明NAC溶栓效应的分子靶点主要是交联动脉血栓中血小板的VWF。
  • NAC与非肽类GpIIb/IIIa抑制剂联用进一步改善溶栓疗效,主要通过加速血栓溶解和防止再血栓形成。
  • 在小鼠大血管血栓栓塞性卒中模型中,该联合治疗显著改善缺血病灶大小和神经结局。
  • NAC未加重出血性卒中结局,提示其发挥溶栓效应而未显著损害正常止血。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Platelet cross-linking during arterial thrombosis involves von Willebrand Factor (VWF) multimers. Therefore, proteolysis of VWF appears promising to disaggregate platelet-rich thrombi and restore vessel patency in acute thrombotic disorders such as ischemic stroke, acute coronary syndrome, or acute limb ischemia. N-Acetylcysteine (NAC, a clinically approved mucolytic drug) can reduce intrachain disulfide bonds in large polymeric proteins. In the present study, we postulated that NAC might cleave the VWF multimers inside occlusive thrombi, thereby leading to their dissolution and arterial recanalization. METHODS: Experimental models of thrombotic stroke induced by either intra-arterial thrombin injection or ferric chloride application followed by measurement of cerebral blood flow using a combination of laser Doppler flowmetry and MRI were performed to uncover the effects of NAC on arterial thrombi. To investigate the effect of NAC on larger vessels, we also performed ferric chloride-induced carotid artery thrombosis. In vitro experiments were performed to study the molecular bases of NAC thrombolytic effect, including platelet aggregometry, platelet-rich thrombi lysis assays, thromboelastography (ROTEM), and high-shear VWF string formation using microfluidic devices. We also investigated the putative prohemorrhagic effect of NAC in a mouse model of intracranial hemorrhage induced by in situ collagenase type VII injection. RESULTS: We demonstrated that intravenous NAC administration promotes lysis of arterial thrombi that are resistant to conventional approaches such as recombinant tissue-type plasminogen activator, direct thrombin inhibitors, and antiplatelet treatments. Through in vitro and in vivo experiments, we provide evidence that the molecular target underlying the thrombolytic effects of NAC is principally the VWF that cross-link platelets in arterial thrombi. Coadministration of NAC and a nonpeptidic GpIIb/IIIa inhibitor further improved its thrombolytic efficacy, essentially by accelerating thrombus dissolution and preventing rethrombosis. Thus, in a new large-vessel thromboembolic stroke model in mice, this cotreatment significantly improved ischemic lesion size and neurological outcome. It is important to note that NAC did not worsen hemorrhagic stroke outcome, suggesting that it exerts thrombolytic effects without significantly impairing normal hemostasis. CONCLUSIONS: We provide evidence that NAC is an effective and safe alternative to currently available antithrombotic agents to restore vessel patency after arterial occlusion.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Martinez de Lizarrondo S, Gakuba C, Herbig BA, et al. Potent Thrombolytic Effect of N-Acetylcysteine on Arterial Thrombi. Circulation. 2017. PMID: 28487393. doi:10.1161/CIRCULATIONAHA.117.027290

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。